Lynparza notches first in POLO trial of pancreatic cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) announced the first positive data for a targeted agent in a molecularly defined subgroup of patients with metastatic pancreatic

Read the full 308 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE